Clinical Trial Update: An Open-Label, Dose-Escalation Study of IMC-20D7S In Participants With Malignant Melanoma [Phase 1]

View source ↗

Summary

Phase 1 open-label dose-escalation study of IMC-20D7S in participants with malignant melanoma has completed; results were posted in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Malignant Melanoma

Drugs mentioned

• IMC-20D7S

Snippet

Sponsor: Eli Lilly and Company | Conditions: Malignant Melanoma | Phase 1 | Status: COMPLETED | Results posted: 2019-06-17